Recursion Pharmaceuticals, Inc. RXRX Business Segments — Clinical development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:ClinicalDevelopmentExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — clinical development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — clinical development?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — clinical development of $6.57M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — clinical development changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — clinical development decreased by 37.8% year-over-year, from $10.56M to $6.57M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — clinical development?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — clinical development has grown at a 12.1% compound annual growth rate (CAGR), from $32.93M to $46.38M.
- What does business segments — clinical development mean?
- Tracks the costs incurred for advancing product candidates through clinical trials and regulatory approval processes. This is a key indicator of the progress and financial burden associated with moving assets from the laboratory to potential commercialization.